Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
SUPN | US
0.29
0.91%
Healthcare
Drug Manufacturers-Specialty & Generic
30/06/2024
19/09/2024
32.13
32.26
32.26
31.78
Supernus Pharmaceuticals Inc. a biopharmaceutical company focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR an extended release topiramate product indicated for the treatment of epilepsy as well as for the prophylaxis of migraine headache; and Oxtellar XR an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition its product candidates include SPN-830 a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817 a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; and SPN-820 a product candidate in Phase II clinical trials for treating resistant depression. The company markets and sells its products through pharmaceutical wholesalers specialty pharmacies and distributors. Supernus Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Rockville Maryland.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
Price Below SMA10D
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
37.8%1 month
28.8%3 months
39.5%6 months
37.1%345.67
20.16
1.79
0.04
0.03
11.49
2.23
1.47
125.64M
1.77B
1.77B
-
10.82
-99.20
24.20
0.56
14.21
18.43
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
5.65
Range1M
5.91
Range3M
9.86
Rel. volume
0.71
Price X volume
7.68M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Harrow Health Inc | HROW | Drug Manufacturers-Specialty & Generic | 46.47 | 1.65B | 2.51% | n/a | 331.16% |
Tilray Inc | TLRY | Drug Manufacturers-Specialty & Generic | 1.78 | 1.50B | -1.11% | n/a | 11.25% |
Collegium Pharmaceutical Inc | COLL | Drug Manufacturers-Specialty & Generic | 38.93 | 1.25B | 0.39% | 14.10 | 258.31% |
OPKO Health Inc | OPK | Drug Manufacturers-Specialty & Generic | 1.59 | 1.10B | -1.85% | n/a | 19.31% |
Evolus Inc | EOLS | Drug Manufacturers-Specialty & Generic | 16.44 | 1.04B | 1.36% | n/a | 656.27% |
PetIQ Inc | PETQ | Drug Manufacturers-Specialty & Generic | 30.76 | 919.29M | -0.06% | 82.92 | 178.54% |
Phibro Animal Health Corporation | PAHC | Drug Manufacturers-Specialty & Generic | 22.41 | 907.69M | 1.17% | 366.50 | 204.74% |
Ironwood Pharmaceuticals Inc | IRWD | Drug Manufacturers-Specialty & Generic | 4.51 | 720.42M | -0.22% | 57.13 | -199.01% |
Pacira Pharmaceuticals Inc | PCRX | Drug Manufacturers-Specialty & Generic | 14.69 | 677.60M | 0.27% | 9.78 | 73.76% |
Canopy Growth Corporation | CGC | Drug Manufacturers-Specialty & Generic | 4.71 | 523.88M | -1.26% | n/a | 117.00% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Fox Factory Holding Corp | FOXF | Recreational Vehicles | 43.37 | 1.81B | 9.44% | 40.19 | 64.69% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 59.55 | 1.72B | 2.69% | 21.09 | 56.33% |
Steelcase Inc | SCS | Building Products & Equipment | 13.31 | 1.52B | -5.67% | 18.14 | 69.98% |
Janus International Group Inc. | JBI | Building Products & Equipment | 10.12 | 1.47B | 1.10% | 11.08 | 116.21% |
REV Group Inc | REVG | Recreational Vehicles | 27.9 | 1.45B | -1.76% | 6.25 | 63.13% |
Pitney Bowes Inc | PBI | Building Products & Equipment | 7.1 | 1.27B | 1.28% | n/a | -571.93% |
ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 11.65 | 1.16B | 2.82% | n/a | 19.46% |
Interface Inc | TILE | Textile Manufacturing | 19 | 1.11B | 1.77% | 16.70 | 106.26% |
Camping World Holdings Inc | CWH | Recreational Vehicles | 24.52 | 1.11B | 0.86% | n/a | 3644.76% |
Malibu Boats Inc | MBUU | Recreational Vehicles | 39.95 | 799.51M | 1.81% | n/a | 1.50% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 11.49 | 16.67 | Cheaper |
Ent. to Revenue | 2.23 | 309.37 | Cheaper |
PE Ratio | 345.67 | 29.14 | Expensive |
Price to Book | 1.79 | 12.81 | Cheaper |
Dividend Yield | - | 2.80 | - |
Std. Deviation (3M) | 39.50 | 75.12 | Lower Risk |
Debt to Equity | 0.04 | -0.93 | Expensive |
Debt to Assets | 0.03 | 0.45 | Cheaper |
Market Cap | 1.77B | 5.22B | Emerging |